Treatment Study
11 patients indicated they took Rituxin treatment as their first series or second series if their first series was Watchful Waiting (3). For this entire group the average response time was 0.75 years and the median response time was 0.7 years. The average age of this group was 53.6 years and the median age was 52.0 years. There dose not seem to be any correlation between age and response time. The age span was from 35 to 69.
1 out of the 11 have indicated they have taken a second series of treatment. The response time for this patient was 1.00 years.
10 patients indicated no other treatment at the time they sent in their profile. The average response time for this group was 0.7 years and the median response time was 0.7 years. If and when profiles are updated with more recent information these numbers need to be recalculated.
8 patients indicated they took a combination treatment with Rituxin. The average response time for this group was 0.8 years and the median response time was 0.8 years. None of this group has had a second series of treatment.
Please note the data supplied by patients were ranges not absolute numbers. For this study the average of the range given were used in calculating the following information. These numbers should only be used to show trends.
There is not enough data (patients) to calculate Blood test averages and median values.
Definitions of terms:
Average: Add all the values
in a set numbers and then divide that sum by total of numbers in the set.
Median: The value in the
center of a set of values.
Response
time: Is from
the start of a series of treatment to the start of the next series of
treatment.
Series: A set number of courses of a drug. This is followed by an undetermined time period not requiring treatment. For example: 3 Courses of 2CdA over a 6 month period (this is one series) or some quantity of Cytoxan daily/weekly over two years (this is also one series).
_______________ indicates patient was on Watchful Waiting before taking their first series of 2CdA.
_______________ indicates patient took a second series of treatment
_______________ indicates patient took a combination treatment with 2CdA.
|
Id |
Private |
Age series1 |
Series |
Treatment |
Date from |
Date to |
Response Time |
Response time |
Response time
(ongoing) |
|
3 |
No |
58.96 |
2 |
Rituxin |
7/1/1999 |
8/1/1999 |
|
0.66 |
0.66 |
|
98 |
No |
50.61 |
2 |
Rituxin Fludarabine (a nucleoside
analogue) Cytoxan (an alkylating
agent) |
3/1/1999 |
3/1/2000 |
|
0.93 |
0.93 |
|
177 |
No |
50.98 |
1 |
Rituxin |
10/1/1999 |
11/1/1999 |
|
0.36 |
0.36 |
|
179 |
No |
57.88 |
1 |
Rituxin Fludarabine (a nucleoside
analogue) |
6/1/1999 |
1/1/2000 |
|
0.70 |
0.70 |
|
304 |
No |
69.48 |
1 |
Rituxin 2Cda (a nucleoside
analogue) Cytoxan (an alkylating agent) |
6/22/1999 |
7/13/1999 |
|
0.67 |
0.67 |
|
410 |
No |
58.47 |
1 |
Rituxin Fludarabine (a nucleoside analogue) |
4/12/1999 |
10/1/1999 |
|
0.91 |
0.91 |
|
458 |
No |
35.90 |
2 |
Rituxin 2Cda (a nucleoside
analogue) Cytoxan (an alkylating
agent) |
11/1/1998 |
1/1/1999 |
|
1.38 |
1.38 |
|
508 |
No |
65.42 |
1 |
Rituxin |
8/1/1999 |
9/1/1999 |
|
0.66 |
0.66 |
|
575 |
No |
52.05 |
1 |
Rituxin 2Cda (a nucleoside analogue) |
3/1/2000 |
8/1/2000 |
|
0.22 |
0.22 |
|
588 |
No |
42.32 |
1 |
Rituxin Fludarabine (a nucleoside
analogue) Other (Specify) |
10/1/1999 |
8/1/2000 |
|
0.71 |
0.71 |
|
590 |
No |
47.56 |
1 |
Rituxin Vincristine |
1/1/1997 |
|
1.00 |
1.00 |
|
_______________ indicates patient was on Watchful Waiting before taking their first series of 2CdA
|
ID |
IgM before 1st |
IgM after 1st |
Series1 .6 Month reduction |
IgM before 2nd |
IgM Most Recent |
WBC before 1st |
WBC after 1st |
Series1 6 Month reduction |
WBC before 2nd |
WBC Most Recent |
RBC before 1st |
RBC after 1st |
Series1 6 Month
reduction |
RBC before 2nd |
RBC Most Recent |
HBC before 1st |
HGB after 1st |
Series1 6 Month reduction |
HGB Before 2nd |
HGB Most Recent |
|
177 |
3749.5 |
|
|
|
2749.5 |
2.7 |
|
|
|
3.2 |
2.7 |
|
|
|
3.2 |
7.7 |
|
|
|
9.7 |
|
179 |
6749.5 |
749.5 |
6000 |
|
749.5 |
5.7 |
3.2 |
2.5 |
|
3.2 |
4.2 |
4.7 |
-0.5 |
|
4.7 |
12.2 |
14 |
-1.8 |
|
14 |
|
304 |
|
1249.5 |
|
|
|
|
2.7 |
|
3.2 |
|
|
3.7 |
|
3.2 |
|
|
12.2 |
|
13.2 |
|
|
410 |
|
1749.5 |
|
|
749.5 |
|
3.2 |
|
|
3.2 |
|
3.7 |
|
|
3.7 |
|
12.7 |
|
|
13.2 |
|
508 |
3749.5 |
4249.5 |
-500 |
|
|
7.5 |
4.2 |
3.3 |
|
|
|
4.7 |
|
|
|
6.7 |
12.2 |
-5.5 |
|
|
|
575 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
588 |
3749.5 |
|
|
|
|
1.7 |
|
|
|
1.7 |
2.5 |
|
|
|
|
8.2 |
|
|
|
|
|
590 |
|
|
|
|
3249.5 |
|
|
|
|
7.5 |
|
|
|
|
4.2 |
|
|
|
|
13.2 |
|
3 |
|
|
|
|
2249.5 |
|
|
|
|
4.7 |
|
|
|
|
4.2 |
|
|
|
|
13.2 |
|
98 |
|
|
|
|
2249.5 |
|
|
|
|
1.2 |
|
|
|
|
2.7 |
|
|
|
|
9.2 |
|
458 |
|
|
|
|
1249.5 |
|
|
|
|
4.2 |
|
|
|
|
|
|
|
|
|
14 |